A prospective, randomized, double-blind, multicentre, parallel-group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia; ZRC-3197) and adalimumab (Humira) in patients with rheumatoid arthritis
一项前瞻性、随机、双盲、多中心、平行组、活性对照研究,旨在比较生物类似药阿达木单抗(Exemptia;ZRC-3197)和阿达木单抗(Humira)在类风湿性关节炎患者中的疗效和安全性。
期刊:International Journal of Rheumatic Diseases
影响因子:2
doi:10.1111/1756-185X.12711
Jani, Rajendrakumar H; Gupta, Rajiv; Bhatia, Girish; Rathi, Gaurav; Ashok Kumar, Patnala; Sharma, Reena; Kumar, Uma; Gauri, Liyakat A; Jadhav, Praveen; Bartakke, Girishchandra; Haridas, Vikram; Jain, Dinesh; Mendiratta, Sanjeev K